Literature DB >> 11972975

Central demyelinating disorders and hepatitis B vaccination: a risk-benefit approach for pre-adolescent vaccination in France.

Daniel Lévy-Bruhl1, Jean-Claude Desenclos, Isabelle Rebière, Jacques Drucker.   

Abstract

The objective of the study was to provide immunization policy decision makers with a risk-benefit analysis for pre-adolescents vaccination, for various scenarios regarding the existence and the strength of an association between hepatitis B vaccination and the occurrence of first episode of central demyelinating (FECD) disease. The risks were assessed as the attributable risks of FECD for various time intervals between vaccination and onset of FECD and the benefits as the number of acute fulminant hepatitis B and cirrhosis prevented in a vaccinated annual cohort. Even in the worst-case considered, the number of complications prevented by the vaccination outweighs quantitatively the potential risks. Even if both sides of the balance are of different medical and sociological nature, this result is in favor of reinforcing the pre-adolescent vaccination strategy in France.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972975     DOI: 10.1016/s0264-410x(02)00053-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

Review 1.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Measles elimination efforts and 2008-2011 outbreak, France.

Authors:  Denise Antona; Daniel Lévy-Bruhl; Claire Baudon; François Freymuth; Mathieu Lamy; Catherine Maine; Daniel Floret; Isabelle Parent du Chatelet
Journal:  Emerg Infect Dis       Date:  2013-03       Impact factor: 6.883

Review 3.  Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines.

Authors:  Olivia Mahaux; Vincent Bauchau; Lionel Van Holle
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-11-25       Impact factor: 2.890

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.